Group 1 - The core point of the article is that Jin Yu Biotechnology Co., Ltd. has successfully completed the first round of clinical trials for its African swine fever subunit vaccine, achieving a protection rate that meets evaluation standards [2] - Since the outbreak of African swine fever in China in 2018, the domestic pig farming industry has suffered economic losses exceeding 1 trillion yuan [2] - The vaccine development has been a collaborative effort involving multiple institutions, with a total investment of nearly 600 million yuan over seven years, focusing on four major technological routes: gene-deleted live vaccines, vector vaccines, subunit vaccines, and mRNA vaccines [2] Group 2 - The African swine fever subunit vaccine received clinical trial approval from the Ministry of Agriculture and Rural Affairs in July 2025, becoming the first subunit vaccine in China to enter clinical stages [2] - The first round of challenge experiments for the vaccine was successfully completed in January 2026, utilizing a genetic engineering subunit technology that expresses only eight conserved antigen proteins, eliminating the risk of virulence reversion [2] - The company has established a high-throughput molecular screening platform, completing AI screening and synthesis of over 100 African swine fever target proteins, providing substantial data for future responses to new strains [3]

Core Viewpoint - The successful completion of the first round of clinical trials for the African Swine Fever (ASF) subunit vaccine by Jinyu Biotechnology Co., Ltd. marks a historic milestone in the animal vaccine industry, providing a potential solution to a long-standing issue in global pig farming [1][2]. Group 1: Vaccine Development - The ASF virus has caused over 1 trillion yuan in economic losses to China's pig farming industry since its introduction in 2018, highlighting the urgent need for effective vaccines [2]. - Jinyu Biotechnology has invested nearly 600 million yuan over seven years in developing various vaccine technologies, including gene-deleted live vaccines, vector vaccines, subunit vaccines, and mRNA vaccines [2]. - The ASF subunit vaccine received clinical trial approval from the Ministry of Agriculture and Rural Affairs on July 14, 2025, becoming the first of its kind to enter clinical trials in China [2]. Group 2: Clinical Trial Results - The first round of challenge experiments concluded successfully in January 2026, showing a 100% survival rate in the immunized group, while the control group experienced a 100% mortality rate [3]. - The vaccine utilizes a genetically engineered subunit technology that expresses eight conserved antigen proteins without live virus, eliminating the risk of virulence reversion [3]. - The vaccine's target has a 99.7% homology with currently circulating recombinant strains, enhancing its effectiveness [3]. Group 3: Technological Integration - The success of the ASF vaccine reflects the integration of AI and biotechnology, with AI accelerating antigen screening and structural optimization [4]. - Jinyu Biotechnology has established the world's first high-throughput target library for ASF, evaluating over 100 proteins to ensure the scientific and effective design of the vaccine [4]. - The company has invested 230 million yuan to build a dedicated GMP production line with an annual capacity of 300 million doses, ensuring consistency from trial to commercialization [4]. Group 4: Future Developments - Jinyu Biotechnology aims to provide a comprehensive solution that includes smart testing, veterinary services, immune purification, and branded food products, moving beyond just vaccine sales [4][5]. - The company is also advancing other innovative vaccines, including an mRNA vaccine for feline infectious peritonitis and a novel mycoplasma vaccine for cattle, which has already been launched [5]. - Future plans include accelerating the registration process for the ASF subunit vaccine and expanding the mRNA vaccine product pipeline, while increasing investments in Southeast Asia to scale up technology, products, and services [5].

Core Viewpoint - The animal health sector experienced a slight decline of 0.23% on January 30, with Jinhe Biological leading the drop. The Shanghai Composite Index closed at 4117.95, down 0.96%, while the Shenzhen Component Index closed at 14205.89, down 0.66% [1]. Group 1: Stock Performance - The closing prices and performance of key stocks in the animal health sector showed varied results, with Huisheng Biological rising by 3.51% to 29.46, while Jinhe Biological fell by 2.98% to 6.51 [1][2]. - The trading volume for Huisheng Biological was 303,100 shares, with a transaction value of 901 million yuan, indicating strong market interest [1]. Group 2: Capital Flow - The animal health sector saw a net inflow of 59.82 million yuan from institutional investors, while retail investors experienced a net outflow of 81.83 million yuan, indicating a shift in investor sentiment [2][3]. - Among individual stocks, Huisheng Biological attracted a significant net inflow of 1.23 billion yuan from institutional investors, while Jinhe Biological faced a net outflow of 543.32 million yuan [3].

Core Viewpoint - The animal health sector experienced a slight decline of 0.2% on January 28, with Yongshun Biological leading the drop, while the overall market indices showed minor gains [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4151.24, up by 0.27% [1]. - The Shenzhen Component Index closed at 14342.9, up by 0.09% [1]. - The animal health sector's performance is summarized in a table showing individual stock movements, with notable gainers including Biological Shares and Jinhai Biological, which rose by 1.51% and 1.49% respectively [1]. Group 2: Stock Performance - Yongshun Biological saw a significant decline of 7.49%, closing at 10.13, with a trading volume of 141,500 shares and a turnover of 145 million yuan [2]. - Other notable decliners included Shoufeng Holdings and Haili Biological, which fell by 2.21% and 2.08% respectively [2]. - The trading volume and turnover for various stocks in the animal health sector are detailed, indicating varied investor interest [2]. Group 3: Capital Flow - The animal health sector experienced a net inflow of 18.02 million yuan from institutional investors, while retail investors saw a net inflow of 9.33 million yuan [2]. - However, there was a net outflow of 27.35 million yuan from speculative funds, indicating a mixed sentiment among different investor types [2]. - A detailed table shows the net capital flow for individual stocks, highlighting significant movements in and out of various companies [3].

Group 1 - The company expects to achieve operating revenue between 1,040 million and 1,080 million yuan for the year 2025, representing an increase of 193.66 million to 233.66 million yuan compared to the previous year, with a year-on-year growth of 22.88% to 27.61% [2] - The company anticipates a net profit attributable to shareholders of the parent company between 24.5 million and 29 million yuan for 2025, indicating a turnaround from a loss in the previous year [2] - The company projects a net profit attributable to shareholders of the parent company, after deducting non-recurring gains and losses, to be between -91 million and -96 million yuan [2] Group 2 - In the previous year, the company reported an operating revenue of 846.34 million yuan, with a total profit of -381.20 million yuan and a net profit attributable to shareholders of the parent company of -378.84 million yuan [4] - The company has focused on innovation and commercialization, leading to sustained revenue growth from its quadrivalent meningococcal vaccine, and has effectively controlled costs, resulting in improved gross margins and overall profitability [4][5] - The company has received significant government subsidies and international funding support due to the rapid advancement of its R&D projects and international collaborations, contributing to substantial non-recurring gains during the reporting period [5]

Core Viewpoint - The company, Jiangsu Sihuan Bioengineering Co., Ltd., is expected to report a negative net profit for the fiscal year 2025, following a financial warning due to previous losses and low revenue [2][4]. Group 1: Performance Forecast - The performance forecast period is from January 1, 2025, to December 31, 2025 [1]. - The company anticipates a net profit in the range of -46 million to -33 million yuan, with revenue expected to be between 330 million and 350 million yuan [4][18]. - The forecast data is based on preliminary calculations by the company's finance department and has not been audited by an accounting firm [2][5]. Group 2: Reasons for Performance Changes - The increase in revenue is primarily attributed to significant growth in seedling sales from the wholly-owned subsidiary, Jiangsu Chenwei Ecological Park Technology Co., Ltd. [3]. - The reduction in net losses is due to decreased asset impairment losses and operating expenses, as well as improved cost control by the subsidiary, Beijing Sihuan Biopharmaceutical Co., Ltd. [3]. Group 3: Risk of Delisting - The company's stock will be subject to delisting risk warnings starting April 30, 2025, due to a negative audited net profit and revenue below 300 million yuan for the fiscal year 2024 [4][10]. - If the company fails to meet certain financial criteria in the 2025 annual report, it may face termination of its stock listing [10][17].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600201 证券简称：生物股份 公告编号：临2026-002 1、本次股份质押基本情况 ■ 2、生物控股本次质押股份未被用作重大资产重组业绩补偿等事项的担保或其他保障用途。 金宇生物技术股份有限公司 关于股东股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 内蒙古金宇生物控股有限公司（以下简称"生物控股"）持有金宇生物技术股份有限公司（以下简 称"本公司"、"公司"）股份 125,474,300 股，占本公司总股本的11.29%。本次股份质押后，其累计质押 本公司股份数量为 34,420,000 股，占生物控股持有本公司股份数量的 27.43 %。 一、公司股份质押情况 公司于2026年1月26日接到股东生物控股函告，获悉其将所持有的本公司 7,420,000 股无限售流通股股票 质押给浙商证券股份有限公司，并办理完成了证券质押相关手续，具体事项如下： 特此公告。 金宇生物技术股份有限公司 董 事 会 2026年1月28日 3、股东 ...

2025年1月1日至2025年12月31日。 2025年年度业绩预告公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 证券代码：688185 证券简称：康希诺 公告编号：2026-002 康希诺生物股份公司 （一）业绩预告期间 （二）业绩预告情况 1、经康希诺生物股份公司（以下简称"公司"）财务部门初步测算，预计2025年年度（以下简称"报告 期"）实现营业收入104,000.00万元到108,000.00万元，与上年同期相比，将增加19,366.19万元到 23,366.19万元，同比增长22.88%到27.61%。 2、预计2025年年度实现归属于母公司所有者的净利润为2,450.00万元到2,900.00万元，与上年同期相 比，将实现扭亏为盈。 3、预计2025年年度实现归属于母公司所有者扣除非经常性损益后净利润为-9,100.00万元到-9,600.00万 元。 （三）本次业绩预告未经注册会计师审计。 二、上年同期业绩情况 公司2024年年度实现营业收入为84,633.81万元，利润总额为 ...

证券日报网讯 1月27日，生物股份发布公告称，公司于2026年1月26日接到股东内蒙古金宇生物控股有 限公司函告，获悉其将所持有的本公司7，420，000股无限售流通股股票质押给浙商证券股份有限公 司，并办理完成了证券质押相关手续。 （编辑 任世碧） ...

（记者 王瀚黎） 每经头条（nbdtoutiao）——国际金价冲破5000美元！7年涨了280%，什么时候才见顶？专家：关键还 看美元，重点关注国际货币体系、降息和科技革命 每经AI快讯，生物股份1月27日晚间发布公告称，内蒙古金宇生物控股有限公司持有金宇生物技术股份 有限公司股份约1.25亿股，占公司总股本的11.29%。本次股份质押后，其累计质押公司股份数量为3442 万股，占生物控股持有公司股份数量的27.43%。 ...